A Liquid-Biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-Inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

液体活检知情平台试验，用于评估 CDK4/6 抑制剂耐药 ER/HER2 转移性乳腺癌的治疗

• 批准号: 462212
• 负责人: Rushton-Marovac Moira K
• 金额: $ 159.11万
• 依托单位: Queen's University (Kingston, Ontario)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2027-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=462212&lang=en
• 关键词: Aromatase Inhibitor And Cdk4/6 Inhibitor Resistance; Biomarker; Circulating Tumour Cells (Ctcs); Circulating Tumour Dna (Ctdna); Hormone-Positive Metastatic Breast Cancer; Liquid Biopsy; Platform Trial; Umbrella Trial

Breast cancers sensitive to the female hormone estrogen (ER+) are the most common subtype of breast cancer, and represent a majority of cases of incurable metastatic disease in Canada and worldwide. Recently, a new class of targeted therapy, called CDK4/6

对雌性激素 (ER+) 敏感的乳腺癌是最常见的乳腺癌亚型，占加拿大和全世界无法治愈的转移性疾病病例的大多数。最近，一类新的靶向治疗药物，称为 CDK4/6